Balyasny Asset Management
VERV

Balyasny Asset Management’s Verve Therapeutics VERV Stock Holding History

Balyasny Asset Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-57,032
Closed -$640K – 3498
2025
Q2 		$640K Sell
57,032
-547,717
-91% -$3.12M ﹤0.01% 2206
2025
Q1 		$2.76M Buy
604,749
+519,633
+610% +$3.48M ﹤0.01% 1549
2024
Q4 		$480K Buy
85,116
+42,701
+101% +$241K ﹤0.01% 2206
2024
Q3 		$205K Sell
42,415
-46,833
-52% -$272K ﹤0.01% 2557
2024
Q2 		$436K Buy
+89,248
New +$561K ﹤0.01% 2108
2021
Q3 		– Sell
-47,749
Closed -$2.88M – 2450
2021
Q2 		$2.88M Buy
+47,749
New +$1.98M 0.01% 903

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Balyasny Asset Management's VERV Position: Q3 2025 in Review

Balyasny Asset Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 57,032 shares — an estimated $640K sold.

Balyasny Asset Management first reported a position in VERV in Q2 2021 and held it in 6 quarters. The position peaked at $2.88M in Q2 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Balyasny Asset Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 57,032 Verve Therapeutics shares in Q3 2025, an estimated $640K.
  • Balyasny Asset Management first reported a position in Verve Therapeutics in Q2 2021 and held it in 6 quarters.
  • Balyasny Asset Management's Verve Therapeutics position peaked at $2.88M in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Balyasny Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.